专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08565898B2 Rate control during AF using cellular intervention to modulate AV node 有权
标题翻译：使用细胞干预调整AV节点的AF期间的速率控制
公开(公告)号：US08565898B2
公开(公告)日：2013-10-22
申请号：US11116621
申请日：2005-04-28
申请人： Vinod Sharma , Daniel C. Sigg
发明人： Vinod Sharma , Daniel C. Sigg
IPC分类号： A61N1/00 , A61K38/00 , A61K38/16
CPC分类号： A61N1/362 , A61K9/0019 , A61K31/221 , A61K38/177 , A61N1/0568
摘要： A biologic intervention method and apparatus generates a persistent modification to an AV node that is physiologically stable after the agent has matured but is alterable with subsequent application of an agent. Specifically, the generic agent is used to modulate a node in a cardiac conduction system including rate control using one and a combination of a family of K+ channel or equivalent. Specifically, the channel is implemented to slow conduction by generating an outward current during optimization of action potential and repolarization phase thus decreasing the current that is available to excite downstream cells. A Kv 1.3 channel, for example, may be used as the biologic channel. The invention enables reversal of the modulation or adjustment for various heart rates (BPM) based on medical and patient-specific needs.
摘要翻译：生物干预方法和装置对于在该药剂已经成熟但随后随后施用药剂而可变化的生理稳定的AV节点产生持久性修饰。具体地，通用代理用于调制心脏传导系统中的节点，包括使用一个K +通道或等效物系的组合的速率控制。具体地，通过在动作电位和复极相优化期间产生向外的电流来实现缓慢传导，从而减少可用于激发下游单元的电流。例如，可以使用Kv1.3通道作为生物通道。本发明能够根据医疗和患者特定的需要逆转各种心率（BPM）的调节或调整。

2. 发明授权

US07778705B2 Electronic and biological pacemaker systems 有权
标题翻译：电子和生物起搏器系统
公开(公告)号：US07778705B2
公开(公告)日：2010-08-17
申请号：US11554770
申请日：2006-10-31
申请人： Daniel C. Sigg , Timothy G. Laske , Vinod Sharma , Orhan Soykan
发明人： Daniel C. Sigg , Timothy G. Laske , Vinod Sharma , Orhan Soykan
IPC分类号： A61N1/00
CPC分类号： A61N1/362 , A61N1/3627
摘要： Heart pacing systems include at least one electronic or biological pacemaker as a primary pacemaker, and at least one electronic or biological pacemaker as a backup pacemaker. When implanted, the primary pacemaker(s) produce primary pacing stimuli that modulate cardiac function. The backup pacemaker(s) provide backup pacing stimuli when the electronic pacemaker is unable to modulate cardiac function at the predetermined pacing rate. The heart pacing systems are implemented by implantation in regions where they can provide pacing stimuli to cardiac tissue.
摘要翻译：心脏起搏系统包括至少一个电子或生物起搏器作为主要起搏器，以及至少一个电子或生物起搏器作为备用起搏器。当植入时，主起搏器产生调节心脏功能的主要起搏刺激。当电子起搏器不能以预定起搏速度调节心脏功能时，备用起搏器提供备用起搏刺激。心脏起搏系统通过植入在可以为心脏组织提供起搏刺激的区域中实现。

3. 发明申请

US20120130303A1 RATE CONTROL DURING AF USING CELLULAR INTERVENTION TO MODULATE AV NODE 审中-公开
标题翻译：在使用细胞干扰调节AV节点的AF期间的速率控制
公开(公告)号：US20120130303A1
公开(公告)日：2012-05-24
申请号：US13359949
申请日：2012-01-27
申请人： Vinod Sharma , Daniel C. Sigg
发明人： Vinod Sharma , Daniel C. Sigg
IPC分类号： A61K31/7052 , A61P9/00 , A61N1/362 , A61K35/00
CPC分类号： A61N1/362 , A61K9/0019 , A61K31/221 , A61K38/177 , A61N1/0568
摘要： A biologic intervention method and apparatus generates a persistent modification to an AV node that is physiologically stable after the agent has matured but is alterable with subsequent application of an agent. Specifically, the generic agent is used to modulate a node in a cardiac conduction system including rate control using one and a combination of a family of K+ channel or equivalent. Specifically, the channel is implemented to slow conduction by generating an outward current during optimization of action potential and repolarization phase thus decreasing the current that is available to excite downstream cells. A Kv 1.3 channel, for example, may be used as the biologic channel. The invention enables reversal of the modulation or adjustment for various heart rates (BPM) based on medical and patient-specific needs.
摘要翻译：生物干预方法和装置对于在该药剂已经成熟但随后随后施用药剂而可变化的生理稳定的AV节点产生持久性修饰。具体地，通用代理用于调制心脏传导系统中的节点，包括使用一个K +通道或等效物系的组合的速率控制。具体地，通过在动作电位和复极相优化期间产生向外的电流来实现缓慢传导，从而减少可用于激发下游单元的电流。例如，可以使用Kv1.3通道作为生物通道。本发明能够根据医疗和患者特定的需要逆转各种心率（BPM）的调节或调整。

4. 发明授权

US08076305B2 Biological pacemakers including mutated hyperpolarization-activated cyclic nucleotide-gated (HCN) channels 有权
标题翻译：生物起搏器包括突变的超极化激活的环核苷酸门控（HCN）通道
公开(公告)号：US08076305B2
公开(公告)日：2011-12-13
申请号：US11565433
申请日：2006-11-30
申请人： Daniel C. Sigg , Vinod Sharma , Yong-Fu Xiao
发明人： Daniel C. Sigg , Vinod Sharma , Yong-Fu Xiao
IPC分类号： A61K48/00 , A01N63/00 , C12N15/74 , C07H21/04
CPC分类号： A61K48/005 , A61K38/00 , C07K14/705
摘要： A composition for implantation into cardiac tissue includes a biological pacemaker that, when implanted, expresses an effective amount of a mutated hyperpolarization-activated and cyclic nucleotide-gated (HCN) isoform to modify Ih when compared with wild-type HCN. Methods for implementing each of the biologocal pacemakers include implanting each of biologocal pacemakers into cardiac tissue.
摘要翻译：用于植入心脏组织的组合物包括生物起搏器，当植入时，与野生型HCN相比，表达有效量的突变超极化激活和环核苷酸门控（HCN）同种型以修饰Ih。实现每个生物定位心脏起搏器的方法包括将每个生物定位心脏起搏器植入心脏组织。

5. 发明申请

US20080103537A1 ELECTRONIC AND BIOLOGICAL PACEMAKER SYSTEMS 有权
标题翻译：电子与生物学系统
公开(公告)号：US20080103537A1
公开(公告)日：2008-05-01
申请号：US11554770
申请日：2006-10-31
申请人： Daniel C. Sigg , Timothy G. Laske , Vinod Sharma , Orhan Soykan
发明人： Daniel C. Sigg , Timothy G. Laske , Vinod Sharma , Orhan Soykan
IPC分类号： A61N1/00
CPC分类号： A61N1/362 , A61N1/3627
摘要： Heart pacing systems include at least one electronic or biological pacemaker as a primary pacemaker, and at least one electronic or biological pacemaker as a backup pacemaker. When implanted, the primary pacemaker(s) produce primary pacing stimuli that modulate cardiac function. The backup pacemaker(s) provide backup pacing stimuli when the electronic pacemaker is unable to modulate cardiac function at the predetermined pacing rate. The heart pacing systems are implemented by implantation in regions where they can provide pacing stimuli to cardiac tissue.
摘要翻译：心脏起搏系统包括至少一个电子或生物起搏器作为主要起搏器，以及至少一个电子或生物起搏器作为备用起搏器。当植入时，主起搏器产生调节心脏功能的主要起搏刺激。当电子起搏器不能以预定起搏速度调节心脏功能时，备用起搏器提供备用起搏刺激。心脏起搏系统通过植入在可以为心脏组织提供起搏刺激的区域中实现。

6. 发明申请

US20110123593A1 SELF-FIXATING SCAFFOLDS 审中-公开
标题翻译：自我修复
公开(公告)号：US20110123593A1
公开(公告)日：2011-05-26
申请号：US13008501
申请日：2011-01-18
申请人： Daniel C. Sigg , Prasanga D. Hiniduma-Lokuge , Vinod Sharma , John L. Sommer
发明人： Daniel C. Sigg , Prasanga D. Hiniduma-Lokuge , Vinod Sharma , John L. Sommer
IPC分类号： A61F2/00 , A61P9/00 , A61P25/00 , A61P35/00 , A61K31/7088 , A61K38/02 , A61K35/12
CPC分类号： A61F2/02 , A61F2/2493 , A61F2250/0067
摘要： A self-fixating scaffold delivers therapeutic material to tissue for treating various diseases/conditions. A scaffold holds the therapeutic material and is implanted into the tissue. A fixation element anchors the scaffold in the tissue making the scaffold less likely to become dislodged.
摘要翻译：自固定支架将治疗材料递送到组织以治疗各种疾病/病症。支架固定治疗材料并植入组织。固定元件将支架锚定在组织中，使得支架不太可能脱落。

7. 发明申请

US20090099611A1 BIOLOGICAL PACEMAKERS INCLUDING MUTATED HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED (HCN) CHANNELS 有权
标题翻译：生物制剂包括突变的高效催化循环核糖核酸（HCN）通道
公开(公告)号：US20090099611A1
公开(公告)日：2009-04-16
申请号：US11565433
申请日：2006-11-30
申请人： Daniel C. Sigg , Vinod Sharma , Yong-Fu Xiao
发明人： Daniel C. Sigg , Vinod Sharma , Yong-Fu Xiao
IPC分类号： A61N1/39 , A61K31/7088 , A61K38/00 , A61K48/00 , A61M31/00 , A61N1/362
CPC分类号： A61K48/005 , A61K38/00 , C07K14/705
摘要： A composition for implantation into cardiac tissue includes a biological pacemaker that, when implanted, expresses an effective amount of a mutated hyperpolarization-activated and cyclic nucleotide-gated (HCN) isoform to modify Ih when compared with wild-type HCN. Methods for implementing each of the biological pacemakers include implanting each of biological pacemakers into cardiac tissue.
摘要翻译：用于植入心脏组织的组合物包括生物起搏器，当植入时，与野生型HCN相比，表达有效量的突变超极化激活和环核苷酸门控（HCN）同种型以修饰Ih。实施每个生物起搏器的方法包括将每个生物起搏器植入心脏组织。

8. 发明申请

US20100274221A1 PRESSURE MONITORING TO CONTROL DELIVERY OF THERAPEUTIC AGENT 有权
标题翻译：压力监测控制治疗药物的输送
公开(公告)号：US20100274221A1
公开(公告)日：2010-10-28
申请号：US12767224
申请日：2010-04-26
申请人： Daniel C. Sigg , Prasanga D. Hiniduma-Lokuge , Mary M. Morris
发明人： Daniel C. Sigg , Prasanga D. Hiniduma-Lokuge , Mary M. Morris
IPC分类号： A61M5/172 , A61B5/03
CPC分类号： A61B5/036 , A61B5/0031 , A61B5/0215 , A61B5/4839 , A61M5/14276 , A61M5/16854 , A61M5/1723 , A61M2005/1726 , A61M2205/3331 , A61M2205/3334
摘要： A method for adjusting delivery of a therapeutic fluid to a patient suffering from or at risk of pulmonary arterial hypertension includes introducing the therapeutic fluid to a patient via a catheter at a predetermined rate. The catheter is positioned to deliver the fluid to the right ventricle or the pulmonary artery. The catheter a one-way valve configured to allow the fluid to flow from the catheter to the target location. The method further includes monitoring pressure of the target location by monitoring internal catheter pressure, and adjusting the rate at which the therapeutic fluid is introduced to the catheter based on the monitored pressure. The rate at which the fluid is introduced to the catheter is increased if internal catheter pressure increases, and the rate at which the fluid is introduced to the catheter is decreased if the internal catheter pressure decreases.
摘要翻译：用于调节对患有或具有肺动脉高压的风险的患者的治疗流体的递送的方法包括以预定的速率经由导管将治疗流体引入患者体内。定位导管以将流体输送到右心室或肺动脉。导管是单向阀，其构造成允许流体从导管流到目标位置。该方法还包括通过监测内部导管压力来监测目标位置的压力，并且基于所监测的压力来调节治疗流体被引入导管的速率。如果内部导管压力增加，流体被引入导管的速率增加，并且如果内部导管压力降低，则将流体引入导管的速率降低。

9. 发明申请

US20100016740A1 CARDIAC PROTECTION SYSTEM AND METHOD 有权
标题翻译：心脏保护系统和方法
公开(公告)号：US20100016740A1
公开(公告)日：2010-01-21
申请号：US12173780
申请日：2008-07-15
申请人： Daniel C. Sigg , James A. Coles, JR. , Dwight H. Warkentin , Deborah Ann Jaye
发明人： Daniel C. Sigg , James A. Coles, JR. , Dwight H. Warkentin , Deborah Ann Jaye
IPC分类号： A61B5/02 , A61N1/00
CPC分类号： A61N1/365 , A61B5/0031 , A61N1/368 , A61N1/3702 , A61N1/37258 , A61N1/37282 , A61N1/37288
摘要： A cardiac ischemic protection system and method for conditioning a patient's heart is provided. The method can include detecting acute myocardial infarction, angina pectoris, silent ischemia, or stunning and providing closed-loop dyssynchronous pacing to the patient's heart to precondition and/or postcondition the patient's heart in order to reduce ischemic damage.
摘要翻译：提供了用于调节患者心脏的心脏缺血保护系统和方法。该方法可以包括检测急性心肌梗塞，心绞痛，静息缺血或惊恐，并向患者的心脏提供闭环异步起搏以预先和/或后置病人的心脏以减少缺血性损伤。

10. 发明授权

US08892197B2 Method and apparatus to control conduction through the heart to treat cardiac conditions 有权
标题翻译：控制心脏传导以治疗心脏病症的方法和装置
公开(公告)号：US08892197B2
公开(公告)日：2014-11-18
申请号：US11192884
申请日：2005-07-29
申请人： Michael R. Ujhelyi , Daniel C. Sigg
发明人： Michael R. Ujhelyi , Daniel C. Sigg
IPC分类号： A61B5/04 , A61M31/00 , A61M5/142 , A61N1/05 , A61M5/172 , A61N1/365
CPC分类号： A61M5/1723 , A61B5/046 , A61M5/14276 , A61M2005/1726 , A61M2210/125 , A61M2230/04 , A61M2230/63 , A61N1/0575 , A61N1/365 , A61N1/3682
摘要： Control of conduction through a heart is described. A lead with a proximal end and a distal end is provided. The distal end of the lead is inserted into a target area. An agent is delivered through the lead to the target area. Delivery of the agent is monitored via a closed loop feedback system.
摘要翻译：描述通过心脏传导的控制。提供具有近端和远端的引线。引线的远端插入目标区域。代理商通过领导交付给目标地区。通过闭环反馈系统监控代理的交付。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式